GALT Galectin Therapeutics Inc

Price (delayed)

$3.17

Market cap

$184.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$163.4M

Highlights
Galectin Therapeutics's quick ratio has shrunk by 86% YoY and by 12% QoQ
The company's net income has shrunk by 81% YoY and by 12% QoQ

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
58.09M
Market cap
$184.16M
Enterprise value
$163.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.97
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$26.16M
EBITDA
-$26.12M
Free cash flow
-$22.61M
Per share
EPS
-$0.45
Free cash flow per share
-$0.4
Book value per share
$0.29
Revenue per share
$0
TBVPS
$0.4
Balance sheet
Total assets
$22.9M
Total liabilities
$4.66M
Debt
$0
Equity
$16.51M
Working capital
$18.13M
Liquidity
Debt to equity
0
Current ratio
4.89
Quick ratio
4.45
Net debt/EBITDA
0.79
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-82.6%
Return on equity
-101.4%
Return on invested capital
N/A
Return on capital employed
-143.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
15.27%
1 week
20.08%
1 month
0%
1 year
21.46%
YTD
41.52%
QTD
-0.94%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.18M
Net income
-$26.25M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 81% YoY and by 12% QoQ
The operating income has dropped by 79% year-on-year and by 12% since the previous quarter

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
10.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has shrunk by 55% YoY and by 10% QoQ
The P/B is 89% above the last 4 quarters average of 5.8 but 59% below the 5-year quarterly average of 26.8
GALT's equity has dropped by 60% year-on-year and by 27% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
The ROA has plunged by 177% YoY and by 30% from the previous quarter
Galectin Therapeutics's ROE has decreased by 38% from the previous quarter

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's quick ratio has shrunk by 86% YoY and by 12% QoQ
GALT's current ratio has shrunk by 85% YoY and by 10% QoQ
The debt is 100% less than the equity
GALT's equity has dropped by 60% year-on-year and by 27% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.